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Abstract
A seeming paradox of sickle cell disease is that patients do not suffer from a high
prevalence of systemic hypertension in spite of endothelial dysfunction, chronic
inflammation and vasculopathy. However, some patients do develop systolic
hypertension and increased pulse pressure, an increasingly recognized major
cardiovascular risk factor in other populations. Hence, we hypothesized that pulse
pressure, unlike other blood pressure parameters, is independently associated with
markers of hemolytic anemia and cardiovascular risk in sickle cell disease. We
analyzed the correlates of pulse pressure in patients (n 5 661) enrolled in a
multicenter international sickle cell trial. Markers of hemolysis were analyzed as
independent variables and as a previously validated hemolytic index that includes
multiple variables. We found that pulse pressure, not systolic, diastolic or mean
arterial pressure, independently correlated with high reticulocyte count (beta 5
2.37, p 5 0.02) and high hemolytic index (beta 5 1.53, p50.002) in patients with
homozygous sickle cell disease in two multiple linear regression models which
include the markers of hemolysis as independent variables or the hemolytic index,
respectively. Pulse pressure was also independently associated with elevated
serum creatinine (beta 5 3.21, p 5 0.02), and with proteinuria (beta 5 2.52, p 5
0.04). These results from the largest sickle cell disease cohort to date since the
Cooperative Study of Sickle Cell Disease show that pulse pressure is
independently associated with hemolysis, proteinuria and chronic kidney disease.
We propose that high pulse pressure may be a risk factor for clinical complications
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of vascular dysfunction in sickle cell disease. Longitudinal and mechanistic studies
should be conducted to confirm these hypotheses.
Introduction
Findings from the landmark Cooperative Study of Sickle Cell Disease (CSSCD)
revealed that sickle cell disease (SCD) patients, particularly those affected by
HbSS, have lower systolic and diastolic blood pressure values compared to age, sex
and race-matched normative values.[1] This large study confirmed findings of
prior smaller series showing lower baseline blood pressure values are characteristic
of SCD patients.[2, 3]
Multiple hypotheses have been formulated over the following years to explain
the paradox of a population affected by severe endotheliopathy and vasculopathy
and accelerated organ damage, yet largely spared from systemic hypertension.
Possible explanations have taken into consideration the role of anemia, resulting
in increased cardiac output with compensatory decreased vascular resistance,
hyposthenuria leading to sodium loss, decreased blood viscosity of oxygenated
sickle blood at low hematocrit levels, and the role of compensatory increases in
cyclooxygenase-2, endothelial nitric oxide synthase, placenta growth factor and
other endothelial-derived factors.[4–7] Again, paradoxically, endothelial function
studies in humans clearly show that many patients, especially those with higher
rates of hemolytic anemia, exhibit impaired response to major endothelial
vasodilators, such as nitric oxide.[6, 8, 9] More recent studies have also shown that
when an appropriate control population is selected and potential confounders are
accounted for statistically, the blood pressure difference between SCD patients
and control subjects is attenuated.[5] Adjustment for the lower BMI of SCD
patients as compared to that of control subjects has proved to be particularly
important in evaluating blood pressure differences.[5, 10, 11] Another possibility
is that systolic, diastolic and mean arterial pressure may not be the systemic
pressure parameters most reflective of SCD vasculopathy. This hypothesis is
supported by recent epidemiological evidence showing that systolic blood
pressure rises as biomarkers of pulmonary hypertension and intravascular
hemolysis increase, while diastolic blood pressure decreases as hemoglobin levels
drop in SCD, leading to subgroups of patients developing systolic hypertension
and increased pulse pressure.[12]
Elevated pulse pressure has recently emerged as an independent predictor of
cardiovascular outcomes and prognostic factor for death in patients at high risk of
cardiovascular morbidity and mortality such as aging patients and those affected
by advanced chronic kidney disease.[13, 14] The main determinants of pulse
pressure are the left ventricular ejection fraction, arterial stiffness, and the timing
and intensity of the backward pressure wave reflections from the periphery of the
vascular system.[15] From the hemodynamic factors that influence pulse pressure,
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two have been shown to independently predict cardiovascular risk: aortic stiffness,
measured from the aortic pulse wave velocity, and early return of reflected waves
to the heart, evaluated from pulse wave analysis.[15] Under physiological
conditions in young subjects, the backward pressure wave returns from the distal
arterial compartment during diastole, cause pulse pressure to be higher in
peripheral than in central arteries, a phenomenon known as pulse pressure
amplification.[15] In conditions where pulse wave velocity and arterial stiffness
are increased, such as SCD,[16] the reflected wave occurs earlier affecting the
central arteries during systole. As a result of this early wave reflection, aortic and
ventricular pressures are increased during systole and aortic pressure is reduced
during diastole,[15] leading to increased pulse pressure. The result of increased
pulse pressure is greater vascular load on the heart, which can lead to myocardial
hypertrophy and heart failure,[17] and end-organ damage in other vascular
districts, including the kidney (reviewed in[18]) and the brain.[19]
Hemolysis in SCD causes endothelial dysfunction via multiple mechanisms,
and both hemolysis and endothelial dysfunction may be independently linked to
elevated pulse pressure. High plasma levels of free hemoglobin from hemolyzed
RBC lead to nitric oxide depletion and reactive oxygen species formation which
cause impaired vascular relaxation and increased arterial stiffness.[20] In addition,
ischemia/reperfusion injury from acute episodes of vaso-occlusion and hemolysis
also lead to the generation of pathologic reactive oxygen species responsible for
endotheliopathy and endothelial inflammation.[21, 22] The hemodynamic
consequences of high baseline hemolysis and anemia are high cardiac output and
decreased peripheral vascular resistance. The combination of increased arterial
stiffness from endothelial dysfunction and a high cardiac output state from severe
hemolysis and anemia are expected to elevate pulse pressure in SCD. We,
therefore, hypothesized that hemolysis would be significantly associated with
pulse pressure in patients with HbSS disease. In the study presented herein, we
report the correlates of pulse pressure in the Treatment of Pulmonary
Hypertension and Sickle Cell Disease with Sildenafil Therapy (walk-PHaSST)
cohort.
Methods
Study Design and Selection of Subjects
The study population and design have been described in detail elsewhere.[23, 24]
Overall, we recruited 720 subjects age 12 and over at steady state from nine
different study sites in the United States and one site in the United Kingdom, 671
(93.2%) of whom enrolled in the study. We analyzed 661 patients with available
systolic and diastolic blood pressure measurements (98.5% of enrolled subjects).
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Ethics Statement
Local institutional review boards (University of Pittsburgh IRB PRO07060076)
approved the protocol and written informed consent was obtained and approved
by the IRB (Clinicaltrials.gov identifier NCT00492531). This study is an analysis
of data from the walk-PHaSST trial.
Evaluation of Subjects
All screening study subjects were evaluated by histories of clinical events and
lifetime treatments, physical examination, laboratory screening, transthoracic
Doppler echocardiography, and the six-minute walk test. Blood pressure was
obtained according to the standard method at each site with the cuff placed in the
forearm and the patient seated. Routine laboratory tests including complete blood
count, serum chemistry profile, lactate dehydrogenase (LDH), urinalysis, urine
albumin, and urine creatinine from samples taken at the subject’s screening visit
were performed in the local laboratories of the participating institutions.
Echocardiography was performed at the participating institutions and read
centrally in the National Heart, Lung and Blood Institute echocardiography core
laboratory. Cardiac measurements were performed according to American Society
of Echocardiography guidelines.[25] Percentage of hemoglobin F was measured
by high-performance liquid chromatography (Ultra Resolution System, Trinity
Biotech, Jamestown, NY). Alpha-thalassemia was detected by molecular
methodology based on polymerase chain reaction at the University of Pittsburgh.
Serum N-terminal pro-brain natriuretic peptide (NT-pro BNP) concentration
was measured by a sandwich immunoassay using polyclonal antibodies that
recognize epitopes located in the N-terminal segment (1–76) of pro-BNP (1–108)
(Elecsys analyser; Roche Diagnostics, Mannheim, Germany). Ferritin was
measured with an enzyme immunoassay (Ramco Laboratories Inc., Stafford, TX).
The eGFR was calculated using the CKD-EPI formula (eGFR in ml/min/
1.73 m25175 6 (serum creatinine)-1.154 6 (age)20.203 6 (0.742 if female) 6
(1.212 if African American)).
Statistical Analysis
Patient characteristics are presented as median and interquartile range (IQR) or
number and percentage of participants with a given characteristic, and
associations with hemoglobin genotype were assessed using the Wilcoxon two-
sample test and the Pearson chi-square test of independence. A hemolytic
component variable was derived using principal component analysis from four
markers of hemolysis - LDH, aspartate aminotransferase (AST), total bilirubin,
and reticulocyte percent - as described elsewhere.[24] This variable produced by
data reduction methodology has strong relationships with indirect and direct
measures of hemolysis, including cell-free hemoglobin levels and red blood cell
microparticle counts.[12] Proteinuria was defined as any positive result from the
urine dipstick test from urine samples taken at the subject’s screening visit. Urine
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albumin and creatinine were available for a subset of subjects and were measured
from spot urine samples taken at the screening visit. Chronic kidney disease
(CKD) was defined according to the National Kidney Foundation, Kidney Disease
Outcomes Quality Initiatives (K/DOQI) guidelines (National Kidney Foundation,
2002) to align the definition of CKD stage to the current evidence-based
guidelines: stage 0 – eGFR. 60 ml/min/1.73 m2 and albuminuria ,30 mg/g
creatinine; stage 1 – eGFR > 90 ml/min/1.73 m2 and albuminuria > 30 mg/g
creatinine; stage 2 – eGFR 60–89 ml/min/1.73 m2 and albuminuria > 30 mg/g
creatinine; stage 3 – eGFR ,60 ml/min/1.73 m2.
Associations of patient characteristics with pulse pressure were assessed using
Spearman correlation coefficients and linear regression analysis, log-transforming
continuous variables as necessary to normalize skewed distributions. Regression
coefficients were tested for significant differences from zero by the t-test. For the
final models, variables were entered in a stepwise approach if they had a
significant univariate association with pulse pressure. All statistical analyses were
performed using SAS, version 9.1 (SAS Institute, Inc., Cary, NC) and Stata,
version 11.1 (Statacorp, LP, College Station, TX).
Results
Patient characteristics by hemoglobin genotype
Most patients enrolled in walk-PHaSST had either HbSS or HbSC and were
analyzed separately. We are reporting their baseline characteristics as these are not
available from prior walk-PHaSST published reports (Table 1). As expected based
on prior epidemiological studies, we found significant differences among subjects
with HbSS and HbSC disease. HbSS patients were significantly younger and had
lower BMI and oxygen saturation than patients with HbSC disease. Among the
blood pressure parameters, pulse pressure was the only one higher in the HbSS
group, while systolic, diastolic and mean arterial pressures were all significantly
higher in HbSC patients. The prevalence of patients on hydroxyurea was higher in
the HbSS group as compared to the HbSC group, which resulted in higher fetal
hemoglobin levels. There was also a higher proportion of patients on chronic
transfusion in the HbSS group, which was accompanied by a higher ferritin value
in this group. HbSS patients had higher markers of hemolysis as measured by
reticulocyte proportion, LDH, AST, total and hemolytic component, all validated
by specific measures of cell free plasma hemoglobin and red cell derived
microparticles.[12] As a result of the higher hemolysis, the total hemoglobin level
was lower in patients with HbSS than in patients with HbSC. A larger proportion
of HbSS patients had proteinuria, a marker of sickle cell nephropathy, recently
shown to be predicted by hemolysis and hemoglobinuria,[26] and chronic kidney
disease stage I or higher. In keeping with these findings, they had a higher
estimated glomerular filtration rate, indicative of worse glomerular hyperfiltra-
tion. Finally, the surrogate markers of pulmonary hypertension TRV and NT-
proBNP were significantly different among the two genotypes.
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Table 1. Patient characteristics by sickle cell disease genotype.
Patient characteristics HbSS patients HbSC patients
n median (IQR)* n median (IQR)* p{
Age, years 500 34 (25–45) 161 41 (28–51) 0.002
Male gender, N (%) 500 245 (49.0) 161 66 (41.0) 0.08
SBP, mmHg 500 117 (109–127) 161 120 (112–132) 0.01
DBP, mmHg 500 67 (60–74) 161 71 (67–80) ,0.0001
MAP, mmHg 500 83 (77–90) 161 88 (82–96) ,0.0001
Pulse pressure, mmHg 500 50 (42–59) 161 48 (41–55) 0.02
Body mass index (BMI) 492 23.0 (20.8–25.8) 160 26.7 (22.7–30.5) ,0.0001
Oxygen saturation{, % 497 97 (95–98) 160 98 (97–99) ,0.0001
Hydroxyurea use, N (%) 500 225 (45.0) 161 21 (13.0) ,0.0001
Transfusions1, N (%) 499 72 (14.4) 159 6 (3.8) 0.0003
Chronic pain, N (%) 499 184 (36.9) 161 78 (48.4) 0.009
Six minute walk, m 492 438 (384–504) 159 440 (363–495) 0.32
WBC, 6 109/L 490 9.7 (7.5–4.3) 156 8.1 (6.4–10.0) ,0.0001
Hemoglobin, mmol/L 489 5.4 (4.7–6.1) 157 6.9 (6.4–7.6) ,0.0001
Hematocrit, % 490 25.2 (22.0–28.4) 157 32.4 (29.4–35.3) ,0.0001
Platelets, 6 109/L 489 364 (285–456) 156 296 (193–362) ,0.0001
Hemoglobin F, % 445 6.3 (2.6–12.4) 139 1.5 (0.8–3.2) ,0.0001
Reticulocytes, % 461 9.1 (6.1–13.4) 153 3.3 (2.5–4.7) ,0.0001
LDH, IU/L 453 422 (299–600) 154 240 (200–321) ,0.0001
Total Bilirubin, mmol/L 490 46.2 (32.5–70.1) 159 22.2 (15.4–34.2) ,0.0001
Hemolytic Component 420 0.6 (20.4–1.4) 148 21.6 (22.3–1.0) ,0.0001
AST, IU/L 477 42 (31–59) 157 26 (21–35) ,0.0001
Ferritin, pmol/L 450 643 (254–1539) 141 263 (148–483) ,0.0001
Albumin, g/L 489 42 (39–44) 157 42 (39–44) 0.59
ALT, IU/L 491 23 (17–33) 159 18 (14–26) ,0.0001
ALP, IU/L 489 90 (70–122) 157 76 (65–102) 0.0002
Creatinine, mmol/L 492 61.9 (50.4–79.6) 159 70.7 (61.9–86.6) ,0.0001
Proteinuria, N (%) 474 162 (34.2) 147 28 (19.0) 0.0005
ACR 306 32 (7.3–220.0) 81 15.2 (4.2–68.4) 0.004
eGFR (ml/min/1.73 m2) 492 138 (109–153) 157 119 (95–137) ,0.0001
CKD||, N (%) 313 173 (55.3) 82 35 (42.7) 0.04
TRV, m/sec 449 2.6 (2.3–2.7) 139 2.4 (2.2–2.7) 0.003
NT-proBNP, pmol/L 464 9.1 (4.0–19.9) 146 5.3 (2.2–12.5) ,0.0001
*Unless otherwise indicated; { From Wilcoxon two-sample test for difference in medians or Pearson chi-square test of independence of groups. p values
,0.002 remained significant after Bonferroni’s adjustment for multiple comparisons; {Hemoglobin oxygen saturation; 1Chronic transfusion therapy; ||Stage I
or higher.
SBP5systolic blood pressure; DBP5diastolic blood pressure; MAP5mean arterial pressure; WBC5white blood cell count; LDH5lactate dehydrogenase;
AST5aspartate aminotransferase; ALT5alanine aminotransferase; ALP5alkaline phosphatase; ACR5 urine albumin-to-creatinine ratio; eGFR5estimated
glomerular filtration rate; CKD5chronic kidney disease; TRV5tricuspid regurgitant jet velocity; NT-proBNP5 N-terminal prohormone of brain natriuretic
peptide.
doi:10.1371/journal.pone.0114309.t001
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Elevated pulse pressure correlates with markers of hemolysis,
elevated creatinine and proteinuria in HbSS patients
We next conducted a univariate analysis of pulse pressure and multiple clinical
and laboratory markers in patients with HbSS and HbSC disease (Table 2). In
HbSS patients, a high pulse pressure was associated with male gender and was
negatively correlated with hemoglobin oxygen saturation. We also found that
pulse pressure was consistently and positively correlated with all markers of
hemolysis, including reticulocyte proportion, LDH, total bilirubin, AST and
hemolytic component (Figure 1, panel A). Finally, pulse pressure was positively
correlated with creatinine (Figure 1, panel B), urine albumin-to-creatinine ratio
and presence of proteinuria (Figure 1, panel C).
In HbSC patients, a different pattern of pulse pressure correlates emerged. In
this group, pulse pressure was positively correlated with age and BMI. There was
no correlation with markers of hemolysis and although, similarly to HbSS
patients, there was a positive correlation with creatinine (Figure 1, panel B), there
was no significant correlation with presence of proteinuria or the urine albumin-
to-creatinine ratio.
In both HbSS and HbSC groups pulse pressure was positively correlated with
TRV.
A complete list of all univariate correlations is reported in Table 2.
Pulse pressure is the only systemic pressure parameter
associated with hemolysis by multiple linear regression in HbSS
patients
We conducted a multiple linear regression analysis to determine which of the
variables that emerged as significant by univariate analysis were able to cross-
sectionally predict the blood pressure variables (systolic, diastolic, mean arterial
and pulse pressure) in the regression model. The following pairs of variables could
not be entered into the model simultaneously due to their high correlation, so we
fitted separate models for each of them: reticulocytes and hemolytic component;
creatinine and estimated glomerular filtration rate; and proteinuria and urine
albumin-to-creatinine ratio. For brevity, we are only reporting the results of the
regression analysis for pulse pressure for HbSS and HbSC patients, separately.
As shown in Table 3, pulse pressure was predicted by hemolysis in HbSS
patients, while systolic, diastolic and mean arterial pressure were not (data not
shown).
In model 1, where the hemolysis markers LDH, AST, total bilirubin, and
reticulocyte proportion were coded as individual variables, the reticulocyte
proportion emerged as a predictor of pulse pressure, together with TRV > 3.0 m/
sec, hemoglobin oxygen saturation, creatinine and proteinuria. In model 2, the
hemolytic component emerged as a significant predictor of pulse pressure in the
regression model. Model 3 and 4 were fitted with the urine album-to-creatinine
ratio replacing proteinuria and showed similar results.
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In hemoglobin SC patients, creatinine (model 1) and estimated glomerular
filtration rate (model 2) and ferritin (both models) were the only predictors of
pulse pressure (Table 3).
Table 2. Correlations of pulse pressure with clinical and laboratory characteristics by hemoglobin genotype.
HbSS patients HbSC patients
n Spearman rho (p)* n Spearman rho (p)*
Age 500 20.005 (0.91) 161 0.18 (0.03)
Male gender, N(%) 500 0.15 (0.0009) 161 0.10 (0.19)
Systolic blood pressure 500 0.66 (,0.0001) 161 0.73 (,0.0001)
Diastolic blood pressure 500 20.29 (,0.0001) 161 20.06 (0.46)
Mean arterial pressure 500 0.09 (0.04) 161 0.33 (,0.0001)
BMI 492 20.02 (0.64) 160 0.26 (0.001)
Hemoglobin oxygen saturation 497 20.17 (0.0001) 160 20.10 (0.22)
Hydroxyurea, current use, N(%) 500 20.02 (0.70) 161 0.009 (0.91)
Chronic transfusion therapy, N(%) 499 20.002 (0.96) 159 20.02 (0.80)
Chronic pain, N(%) 499 20.03 (0.47) 161 20.06 (0.47)
Six minute walk, m 492 0.09 (0.04) 159 0.03 (0.71)
White blood cells 490 0.09 (0.04) 156 0.11 (0.15)
Hemoglobin 489 20.06 (0.17) 157 20.009 (0.91)
Hematocrit 490 20.07 (0.13) 157 0.02 (0.79)
Platelets 489 0.02 (0.61) 156 0.02 (0.81)
Hemoglobin F 445 20.01 (0.81) 139 0.02 (0.81)
Reticulocytes 461 0.16 (0.0006) 153 0.10 (0.20)
Lactate dehydrogenase 453 0.15 (0.001) 154 0.07 (0.41)
Total Bilirubin 490 0.11 (0.02) 159 0.001 (0.99)
Hemolytic Component 420 0.21 (,0.0001) 148 0.09 (0.28)
Aspartate aminotransferase 477 0.13 (0.006) 157 0.13 (0.12)
Ferritin 450 20.05 (0.28) 141 0.22 (0.008)
Albumin 489 20.09 (0.06) 157 20.05 (0.54)
Alanine aminotransferase 491 0.08 (0.07) 159 0.20 (0.01)
Alkaline Phosphatase 489 0.09 (0.04) 157 0.03 (0.68)
Creatinine 492 0.10 (0.02) 159 0.28 (0.0004)
Protein in urine 474 0.16 (0.0005) 147 0.02 (0.82)
Urine album-to-creatinine ratio 306 0.15 (0.01) 81 0.20 (0.08)
Estimated glomerular filtration rate 492 20.006 (0.9) 157 20.25 (0.002)
Chronic kidney disease 313 0.16 (0.006) 82 0.23 (0.04)
Tricuspid regurgitant jet velocity 449 0.20 (,0.0001) 139 0.20 (0.02)
NT-proBNP{ 464 0.09 (0.06) 146 0.12 (0.16)
*p values ,0.002 remained significant after Bonferroni’s adjustment for multiple comparisons.
{N-terminal prohormone of brain natriuretic peptide.
doi:10.1371/journal.pone.0114309.t002
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Discussion
Pulse pressure is emerging as an important risk factor for end-organ damage and
cardiovascular morbidity and mortality in many conditions (reviewed in [18]).
While several studies have explored the associations of systolic blood pressure in
SCD, the role of pulse pressure has never been thoroughly investigated in this
disease.
Our study shows that pulse pressure is predicted by hemolysis in patients with
HbSS from the walk-PHaSST international multi-center cross-sectional cohort.
To our knowledge, this is the largest SCD cohort since the CSSCD, a natural
history study that followed SCD patients in the pre-hydroxyurea era. A striking
finding of the CSSCD was that SCD patients, and particularly those with HbSS
had lower overall median systolic blood pressure (113 ¡ 14.5 mmHg) than
normative controls, a difference observed for all age groups and both sexes.[1] In
the hydroxyurea era, the UNC cohort was characterized by a higher systolic blood
pressure (122 ¡ 15 mmHg) which was not significantly different from that of
age-matched African American control subjects.[5] Both and other studies have
shown that elevations of systolic blood pressure over baseline are detrimental in
SCD patients and predict a risk of vascular complications including stroke,[1, 27]
kidney disease,[28, 29] and pulmonary hypertension.[24] It is, however, intriguing
that while high baseline hemolysis is independently correlated with these
complications, no association had been found between systolic blood pressure and
severity of hemolysis.[5] Our findings of a lack of association between markers of
hemolysis and systolic blood pressure in multiple regression analysis in the walk-
PHaSST cohort confirm these prior reports. We, therefore, hypothesized that the
detrimental effect of systolic blood pressure may be mediated by pulse pressure
elevation in response to hemolysis-derived vasculopathy. To this day, little
Figure 1. Correlates and associations of pulse pressure with kidney function and hemolysis. A, Pulse pressure has a significant positive correlation
with the hemolytic component in HbSS patients, but not in HbSC patients. B, Pulse pressure has a significant positive correlation with serum creatinine in
both HbSS and HbSC patients. C, Elevated pulse pressure is significantly associated with presence of proteinuria in HbSS patients, while the association is
not significant in HbSC patients.
doi:10.1371/journal.pone.0114309.g001
Pulse Pressure in Sickle Cell Disease
PLOS ONE | DOI:10.1371/journal.pone.0114309 December 5, 2014 9 / 14
attention has been devoted to pulse pressure in SCD, an increasingly recognized
cardiovascular risk factor. While the mechanistic link between hemolysis, pulse
pressure and vascular complications cannot be proven in an epidemiological
cross-sectional study, our findings do suggest that elevated pulse pressure may be
more reflective of the peculiar vasculopathy of SCD, where hemolysis causes
increased arterial stiffness from nitric oxide depletion and decreased peripheral
vascular resistance from anemia, leading to elevated pulse pressure. Moreover,
hemolysis is also linked to microvascular dysfunction in SCD, since the primary
pathogenic process in this disease occurs at the level of the post-capillary venules
and is characterized by cellular adhesion, vaso-occlusion, hemolysis and ischemia-
reperfusion injury.[30] Microvascular damage would lead to loss of small vessels
and consequent increased arterial stiffness which would elevate pulse pressure.
Table 3. Independent predictors of pulse pressure.
Beta (95% CI) p Standardized beta
HbSS patients
Model 1 (n5387)
Reticulocytes*, % 2.07 (0.1–4.0) 0.04 0.11
TRV, m/sec 13.03 (5.2–20.9) 0.001 0.17
Hemoglobin oxygen saturation 20.42 (–0.79–0.05) 0.03 20.12
Creatinine* 2.88 (0.19–5.58) 0.04 0.11
Proteinuria 2.58 (0.20–4.97) 0.03 0.11
Model 2 (n5352)
Hemolytic component 1.37 (0.4–2.3) 0.006 0.16
TRV, m/sec 10.04 (1.7–18.4) 0.02 0.13
Hemoglobin oxygen saturation 20.34 (20.7–0.05) 0.09 20.10
Creatinine* 3.34 (0.6–6.1) 0.02 0.13
Proteinuria 2.57 (0.08–5.0) 0.04 0.11
Model 3 (n5281)
Reticulocytes*, % 2.42 (0.3–4.6) 0.03 0.13
Urine albumin-to-creatinine ratio* 0.64 (0.01–1.3) 0.05 0.12
Creatinine* 3.22 (0.2–6.2) 0.03 0.13
Model 4 (n5263)
Hemolytic component 1.50 (0.4–2.6) 0.006 0.17
Urine albumin-to-creatinine ratio* 0.56 (20.1–1.2) 0.09 0.11
Creatinine* 4.00 (0.8–7.2) 0.01 0.16
HbSC patients
Model 1 (n5140)
Creatinine* 9.65 (3.0–16.3) 0.005 0.23
Ferritin* 2.66 (0.7–4.6) 0.008 0.22
Model 2 (n5138)
eGFR 20.08 (20.14, 20.02) 0.01 20.21
Ferritin* 2.63 (0.724.6) 0.009 0.22
*transformed using the natural log function.
doi:10.1371/journal.pone.0114309.t003
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Elevated pulse pressure would in turn damage small vessels and lead to
microvascular rarefaction in a vicious cycle.[18, 31] It is, therefore, possible that
hemolysis may mechanistically link both micro and microvascular dysfunction
and that elevated pulse pressure may be a result of cross-talk between large and
small caliber vessels as documented in hypertensive patients.[18] The link between
hemolysis and pulse pressure is also supported by our finding that hemolysis was
not associated with pulse pressure in HbSC, a subgroup of SCD which is not
characterized by high level hemolysis and whose disease manifestations may
result, instead, from increased blood viscosity.
As other studies have shown,[5, 32] we found a strong correlation between all
pressure parameters and kidney function measured as serum creatinine and
proteinuria. This finding reinforces the importance of systemic blood pressure as a
predictor of kidney deterioration in SCD. Since abnormalities in kidney function
are among the most sensitive and earliest biomarkers of microvascular
dysfunction in SCD,[33] it may be important to therapeutically target blood
pressure early and aggressively, to prevent this complication. While angiotensin-
converting enzyme inhibitors may reduce proteinuria in SCD patients,[34] there
is no clear evidence to show which patients may benefit the most from these
medications. In particular, it is not known what the optimal blood pressure
threshold to initiate angiotensin-converting enzyme inhibitor therapy should be
and whether reduction of albuminuria predicts long term clinical outcomes such
as need for renal replacement therapy and death. Based on our results, treatments
aimed at reducing hemolysis may, however, also benefit the kidney microvascular
district, independently from other therapeutic pathways.
We also found a significant association between BMI and pulse pressure in
HbSC patients, but not in HbSS patients. In HbSC patients, we also observed an
interaction of gender and BMI, with associations of BMI with pulse pressure
observed in males but not in females (data not shown). BMI has been positively
correlated with pulse pressure in other populations without SCD,[35] thus
suggesting that in older HbSC patients with increased BMI, obesity may have the
same adverse impact on arterial compliance observed in populations exposed to
routine cardiovascular risk factors. It is intriguing to hypothesize that other co-
morbid conditions such as dyslipidemia and diabetes may mediate the association
between BMI and pulse pressure in HbSC patients.
Finally, we found significant independent associations between hemoglobin
oxygen saturation and pulse pressure in HbSS patients and ferritin and pulse
pressure in HbSC patients. We hypothesize that the inverse relationship between
hemoglobin oxygen saturation and pulse pressure in HbSS patients may be either
the result of increased cardiopulmonary disease burden in patients with high pulse
pressure, as also shown by the association with elevated TRV, or worse anemia
secondary to hemolysis. As shown inTable 1, patients with HbSC had significantly
lower ferritin than HbSS patients with the IQ range below 500 pmol/L. Patients
with HbSC have significantly lower burden of hemosiderosis as compared to
HbSS patients as they are less frequently transfused due to higher baseline
hemoglobin. Thus, values in the range observed in this study may be more
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reflective of an enhanced inflammatory state. If this hypothesis is correct, pulse
pressure may be positively correlated with increased inflammation in HbSC
patients from our cohort.
The main limitation of our study is that the walk-PHaSST clinical cohort was
not designed to specifically evaluate baseline systemic blood pressure in SCD
patients. Thus, data on the history of hypertension or use of antihypertensive
medications are not available for our population. The use of principal
components analysis to derive a hemolytic component variable from several
correlated variables all related to hemolysis is an additional limitation because of
potentially important associations that could have been missed by using a data
reduction technique such as PCA. Finally, eGFR and creatinine are relatively poor
markers of kidney function in sickle cell disease due to glomerular hyperfiltration
and increased creatinine excretion by the proximal tubule in this disease. It is,
unfortunately, not possible to infer which patient subsets may have experienced
worse hyperfiltration and the confounding effect of this phenomenon, although it
is safe to assume that glomerular hyperfiltration decreased with increasing age in
our population. Associations of eGFR with pulse pressure did not, however,
change after adjustment for age. Our results are also strengthened by the
availability of values of proteinuria and albumin to creatinine ratio in a subset of
patients. These are recognized valuable screening tools of kidney dysfunction by
the recently published sickle cell guidelines.[36]
In summary, our results show that pulse pressure is closely linked to hemolysis
in SCD and suggest that it may be an important predictor of cardiovascular risk.
Longitudinal and mechanistic studies should be conducted to confirm these
hypotheses. Moreover, measurement of pulse wave velocity may provide further
information on arterial stiffness and its relationship to pulse pressure and
microvascular dysfunction in SCD.
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